Previous 10 | Next 10 |
2023-11-21 05:30:00 ET All eyes have been on Eli Lilly (NYSE: LLY) in recent times as it prepared to increase its earnings potential in the billion-dollar weight-loss treatment market. Lilly already has generated blockbuster revenue from Mounjaro, a diabetes drug doctors have also p...
2023-11-20 13:40:05 ET Summary The Gabelli Dividend & Income Trust provides a more value-oriented portfolio, and its discount presents a buying opportunity for the long-term investor. The GDV closed-end fund has paid a consistent monthly distribution for most of its life, with...
2023-11-20 11:41:00 ET Summary Disney CEO Iger to hold a company-wide town hall next week to discuss future opportunities. Moody's raises SoftBank's credit outlook from negative to stable. Goldman strategist David Kostin says that rate cuts probably won’t happen until l...
2023-11-20 06:29:52 ET More on the markets SPY: Sell The Rally - Historical Patterns Show Misplaced Optimism S&P 500: Forget The Year-End Rally The Message From 12 Post-CPI Charts Catalyst watch: Nvidia earnings, Broadcom-VMware drama, auto show buzz and ...
2023-11-19 12:00:00 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly: Perfectly Priced Healthcare Giant Novo Nordisk A/S (NVO) Novo Nordisk R&D Investor Event (Transcript) Eli Lilly: Favorable Developments Continue Regarding Anti-Obesity Drug Franchise ...
2023-11-19 06:05:00 ET Just about every evening when I sit down for dinner and turn on the television, a series of commercials with catchy jingles grabs my attention. It's always the same ads, each promoting a treatment from a pharmaceutical company . The most recognizable commercials a...
2023-11-17 16:16:14 ET More on Lonza Group AG Lonza: The Day Has Come, And We Lower Our Expectation Lonza Group: Downside Scenario Already Priced In Historical earnings data for Lonza Group AG Dividend scorecard for Lonza Group AG Financial informatio...
2023-11-17 09:20:22 ET Summary Medtronic plc will announce its fiscal year 2024 Q2 earnings Tuesday 21st November. Analysts expect Q2 revenues of ~$7.9bn, normalized EPS of $1.18, and GAAP EPS of $0.81. Key areas of focus include the impact of U.S.-China relations, supply chai...
2023-11-17 08:45:44 ET Palm Beach, FL – November 17, 2023 – FinancialNewsMedia.com News Commentary – The global diabetes therapy and treatment market is driven primarily by increased diabetes prevalence, sedentary lifestyles, and most other chronic diseases,...
2023-11-17 08:24:15 ET More on Eli Lilly Eli Lilly: Perfectly Priced Healthcare Giant Eli Lilly: Favorable Developments Continue Regarding Anti-Obesity Drug Franchise Eli Lilly and Company (LLY) Presents at UBS Biopharma 2023 Conference (Transcript) Eli Lilly...
News, Short Squeeze, Breakout and More Instantly...
Lilly's tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity PR Newswire Tirzepatide reduced the risk of heart failure outcomes – heart failure urgent visit or hospitalization , oral diuret...
2024-07-30 07:07:00 ET If your portfolio doesn't have exposure to the biopharma businesses pursuing the development of weight loss medicines, it might be time to consider changing that situation. With an influx of new drugs for sale, and many competitors looking to secure their share of the...
2024-07-30 05:48:00 ET Going into 2024, DexCom 's (NASDAQ: DXCM) shares were up a whopping 14 times over the last 10 years. The company's continuous glucose monitoring (CGM) devices enjoyed tremendous demand from individuals with diabetes. However, last week was the worst for De...